Debt Financing

IM Cannabis takes US$1.02 million for a US$1.2 million note from L.I.A. Pure Capital, with warrants for 3.9 million shares

IMCC

The variable-price note can convert as low as US$0.1449 a share, and the warrant alone is about 2.4 times the shares outstanding in October. The going concern company can ask the same lender for more notes every quarter from January.

Investor Chat

Scorecard

IMCCDebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-05
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-05
Mixed record
Investment Attractiveness: 5/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Mixed

Debt: loan financing

By the aibio.space news desk

Technicians in clean suits at a large instrument
Technicians in clean suits at a large instrument. Photo: NASA (KSC), Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

IM Cannabis Corp. (Nasdaq: IMCC) sold a US$1,200,000 convertible note on November 4, 2026 to L.I.A. Pure Capital Ltd. of Tel Aviv, and the cash it actually received was US$1,020,000. With the note came a warrant for up to 3,936,330 common shares, about 2.4 times the 1,647,494 shares the company reported outstanding on October 7. The press release headline speaks of US$1,200,000 of "gross proceeds" and does not name the buyer, whose name appears only in the purchase agreement filed with the 6-K. The 6-K was signed by Chief Executive Officer and director Oren Shuster. In our reading, for a company whose own accounts carry a going concern warning, this is another small raise on terms that can turn into a large number of new shares. Form 6-K

What the note costs

The purchase agreement sets the price of the initial note at US$1,020,000 for US$1,200,000 of principal, the 15% original issue discount. The note pays 4% a year, rising to 14% during an event of default. It matures 28 months after issuance and is repaid in 10 equal monthly instalments that start after month 18. Securities purchase agreement

Pure Capital can convert any part of the balance at the lower of a fixed US$0.610 per share or 85% of the lowest daily volume-weighted average price over the 20 trading days before conversion, but not below a floor of US$0.1449. On principal alone, conversion at the fixed price would mean about 1.97 million shares, and at the floor about 8.28 million. A 4.99% ownership cap applies. In our reading, it limits how much the holder owns at one time, not how much it can convert and sell over time. For comparison, the company sold shares at US$2.00 in a registered direct offering on September 24, and its stock last traded at US$1.90 on October 7, according to its October F-3. Press release

The warrant is exercisable at US$0.610 per share from November 4, 2026 until November 3, 2029. Its size is set at 200% of the shares the note converts into at the fixed price. It has anti-dilution and ratchet provisions that the release does not explain.

A standing facility

From January 1, 2027, the company may ask Pure Capital to buy more notes, at 85% of principal, of up to US$1,200,000 in each three-month period, each with its own warrant. The agreement words this as a request that the buyer "shall purchase", subject to the closing conditions. The release states no overall cap. Securities purchase agreement

This is not a first deal with this lender. IM Cannabis signed a US$2 million loan agreement with L.I.A. Pure Capital Ltd. in July 2025, according to its second-quarter MD&A, and its September prospectus refers to private placements of notes and warrants to the same firm that closed on July 1, August 7 and September 2, 2026. That prospectus warns that the shares registered for resale "could create a significant overhang". An F-3 filed on October 8 covers the resale of up to 2,799,276 shares. September 424B5

Agents and counsel

The release and 6-K name no placement agent, underwriter or finder. The agreement sends copies of notices to the company to Sullivan & Worcester LLP in New York. The notes were sold under Section 4(a)(2) and Regulation D, with a Canadian hold period of four months and one day. The company must file a resale F-3 within 30 trading days of closing and have it declared effective within 60 days, or 90 days if the SEC does a full review.

The business behind the raise

The company now runs only its Israeli medical cannabis business, after selling I.M.C. Holdings, which held its German and other European operations, to Slil.com Holding Ltd. on September 29. Sale release

For the six months to June 30, 2026, revenue fell to C$16.3 million from C$25.2 million and the net loss widened to C$6.9 million from C$0.02 million. Israel produced C$7.3 million of that revenue, down from C$10.7 million, and a segment loss of C$2.0 million. At June 30 the company had C$1.6 million of cash, a working capital deficit of C$13.1 million and a shareholders' deficit of C$5.5 million. Management says these conditions raise substantial doubt about its ability to continue as a going concern. Q2 results

The company regained compliance with Nasdaq's US$1.00 minimum bid rule on September 23, after a 1-for-30 share consolidation that took effect on August 27, according to the September prospectus. Its own release lists the risk of defaulting on existing debt and of not meeting Nasdaq listing requirements. In September it also signed a non-binding letter of intent to buy 51% of Space Defense Innovations LLC, a Polish drone distributor, for shares and a seller loan. September 23 release

Next to watch are the resale F-3 for these shares, the first conversions, and whether the company calls on the quarterly facility after January 1.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.